Scarica l'app Stockscreener
3.95
0.75%
-0.03
Dopo l'orario di chiusura:
3.96
0.010
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.98
Aprire:
$3.99
Volume 24 ore:
139.08K
Relative Volume:
1.41
Capitalizzazione di mercato:
$75.58M
Reddito:
-
Utile/perdita netta:
$-24.05M
Rapporto P/E:
-1.8372
EPS:
-2.15
Flusso di cassa netto:
$-17.78M
1 W Prestazione:
-6.40%
1M Prestazione:
+12.54%
6M Prestazione:
+28.66%
1 anno Prestazione:
-22.09%
Intervallo 1D:
$3.90
$4.06
Intervallo di 1 settimana:
$3.86
$4.36
Portata 52W:
$2.0278
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
Nome
Envveno Medical Corporation
Settore
Industria
Telefono
949-261-2900
Indirizzo
70 DOPPLER, IRVINE
Confronta NVNO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.95 | 75.58M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Envveno Medical Corporation Borsa (NVNO) Ultime notizie
Jane Street Group LLC Acquires New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoV - GuruFocus
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - The Oklahoman
enVVeno Medical (NVNO) Showcases Promising Two-Year Data for Ven - GuruFocus
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoValve Trial Results | NVNO Stock News - GuruFocus
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pi - GuruFocus
enVVeno Medical announces two-year data from VenoValve pivotal study - TipRanks
enVVeno Medical announces interim two-year follow-up data on VenoValve trial - TipRanks
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting | NVNO Stock News - GuruFocus
VenoValve Shows 83% Success Rate in 2-Year Trial Data, FDA Decision Due 2025 | NVNO Stock News - Stock Titan
enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Up 19.4% in May - Defense World
NVNBWForm FWPFiling under Securities Act Rules 163/433 of free writing prospectuses - mx.advfn.com
Northern Trust Corp Raises Holdings in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical surges 70% following InvestingPro’s Fair Value signal By Investing.com - Investing.com India
enVVeno Medical appoints Jennifer Bright as financial chief - MSN
enVVeno Medical Appoints New Chief Financial Officer - TipRanks
enVVeno Medical appoints new CFO amid growth phase By Investing.com - Investing.com South Africa
EnVVeno Medical Names Jennifer Bright as CFO - Orange County Business Journal
enVVeno Medical (NVNO) Appoints New CFO Jennifer Bright | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Appoints New CFO, Jennifer Bright | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Appoints New CFO Jennifer Bright | NVNO S - GuruFocus
enVVeno Medical appoints Jennifer Bright as CFO - TipRanks
EnVVeno Medical Names Jennifer Bright CFO - marketscreener.com
enVVeno Medical appoints new CFO amid growth phase - Investing.com
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer | NVNO Stock News - GuruFocus
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - ACCESS Newswire
Dimensional Fund Advisors LP Decreases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
EnVVeno has first-in-human valve data, expects FDA decision this year - MassDevice
NVNO's VenoValve Shows Promising Three-Year Outcomes in Publishe - GuruFocus
Three-Year VenoValve(R) First-in-Human Trial Data Published in t - GuruFocus
Three-year VenoValve first-in-human trial data show high patency rate - Venous News
enVVeno Medical (NVNO) Reveals Promising Three-Year VenoValve Ou - GuruFocus
enVVeno Medical publishes three-year VenoValve data - TipRanks
enVVeno Medical (NVNO) Reveals Promising Three-Year VenoValve Outcomes | NVNO Stock News - GuruFocus
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - ACCESS Newswire
Geode Capital Management LLC Increases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO: Financial Position Supports Key Developments Ahead | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve Progress | NVNO Stock News - GuruFocus
enVVeno Medical Reports First Quarter 2025 Financial Results and - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Corsicana Daily Sun
enVVeno Medical Reports Strong Q1 Financials with $38.9M War Chest for VenoValve FDA Launch - Stock Titan
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
JPMorgan Chase & Co. Buys New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
Envveno Medical Corporation Azioni (NVNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Envveno Medical Corporation Azioni (NVNO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gray Robert | Director |
Dec 31 '24 |
Buy |
2.94 |
3,500 |
10,290 |
11,155 |
| Shrivastava Sanjay | Director |
Dec 24 '24 |
Buy |
2.90 |
5,400 |
15,660 |
9,288 |
| Jenusaitis Matthew | Director |
Dec 19 '24 |
Buy |
2.53 |
9,620 |
24,339 |
16,545 |
| BERMAN ROBERT ANDREW | Chief Executive Officer |
Dec 19 '24 |
Buy |
2.55 |
12,000 |
30,600 |
222,236 |
0.54%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):